trending Market Intelligence /marketintelligence/en/news-insights/trending/sebmZAIWUSGAchHY5f1Onw2 content esgSubNav
In This List

AMAG closes licensing agreement for Endoceutics' dyspareunia drug

Blog

Insight Weekly: US bank stress tests; cracks in housing market; summer energy supply risks

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches


AMAG closes licensing agreement for Endoceutics' dyspareunia drug

AMAG Pharmaceuticals Inc. closed a licensing agreement with Endoceutics Inc. for exclusive U.S. commercial rights to Intrarosa, a drug for the treatment of moderate-to-severe dyspareunia, a common symptom of vulvar and vaginal atrophy, due to menopause.

Intrarosa was approved in November 2016 and AMAG expects to launch Intrarosa in the U.S. in mid-2017.

Endoceutics and AMAG have also agreed to co-develop the product as a potential treatment for female sexual dysfunction in post-menopausal women.